WoS İndeksli Yayınlar Koleksiyonu

Permanent URI for this collectionhttps://hdl.handle.net/20.500.14627/6

Browse

Filters

2021 - 202633

Settings

Access Right: Closed AccessPublisher: search.filters.publisher.Elsevier

Search Results

Now showing 1 - 10 of 33
  • Article
    Synthesis, Experimental and Quantum Mechanical Investigation of the Crystal Structures of Two Triazolyl-Indole Compounds, along with the Evaluation of Their Antioxidant Activity
    (Elsevier, 2026) Pınar, Deniz; Kurt-Şirin, Özlem; Ulusoy-Güzeldemirci, Nuray; Dincel, Efe Doğukan; Karayel, Arzu; Kuran, Ebru Didem
    In this study, two 1,2,4-triazolyl-indole compounds, 5-(1H-indol-3-yl)-4-propyl-2,4 dihydro-3H-1,2,4-triazole-3-thione (3a) and 5-(1H-indol-3-yl)-4-butyl-2,4-dihydro-3H-1,2,4-triazole-3-thione (3b), were synthesized and the structures of these compounds were determined by X-ray diffraction method. These two compounds crystallize in the orthorhombic space groups, Pbca. The structures have been determined by direct methods and refined to R, 0.0459 (3a) and 0.0714 (3b). The molecular and crystal structures are stabilized by two intermolecular hydrogen bond for both molecules. The triazole parts of the molecules are almost perpendicular to propyl and butyl groups. NMR studies was also performed to enhance comprehension of the molecular structure of the compounds. The most stable states of the structures, as determined by both DFT analysis and experimental realizations (X-ray, NMR and FT-IR), are the thione form. Although the thione forms are thermodynamically more stable than the thiol forms (Delta H degrees approximate to-15 kcal/mol), they display higher chemical reactivity, as reflected by their smaller HOMO-LUMO energy gaps (Delta E = 4.374 eV for 3a and 4.377 eV for 3b). In addition, the antioxidant activities of both compounds were evaluated using ABTS, DPPH, and FRAP assays. Although both (3a) and (3b) exhibited measurable radical scavenging and reducing power, their antioxidant capacities were found to be lower than that of the reference compound quercetin.
  • Conference Object
    Comparison of the Effectiveness of Connective Tissue Massage and Classical Massage in Patients with Migraine
    (Elsevier, 2025) Ozdincler, Arzu Razak; Kaya, Begum Kara; Kahleogullari, Elif
  • Article
    New Diclofenac Hydrazones: Design, Synthesis, in Silico Studies and Anticancer Evaluation Against Breast Cancer
    (Elsevier, 2026) Birgul, Kaan; Oktay, Lalehan; Bekci, Hatice; Cikla-Suzgun, Pelin; Durdagi, Serdar; Kucukguzel, S. Guniz
    Breast cancer remains one of the most prevalent and lethal malignancies among women, highlighting the urgent need for novel therapeutic strategies that can overcome resistance mechanisms. The p38 alpha mitogen-activated protein kinase (MAPK14) plays a key role in inflammation-associated oncogenic signaling, making it an attractive molecular target for drug development. In this study, a novel series of diclofenac-based hydrazone derivatives (4a-4o) were designed, synthesized, and characterized using FT-IR, 1H- and 13C-NMR spectroscopy, thin-layer chromatography, and elemental analysis. Computational target profiling using SwissTargetPrediction identified MAPK14 as the primary predicted target. Molecular docking against the MAPK14 crystal structure (PDB ID: 1WBS) revealed high binding affinities (-11.41 to -8.34 kcal/mol), supported by MM/GBSA free energy calculations and molecular dynamics simulations, which confirmed stable ligand-protein interactions through hydrogen bonding with Asp168 and Glu71. In vitro cytotoxicity assays on MCF-7 (luminal A) and MDA-MB-231 (triple-negative) breast cancer cell lines demonstrated low-micromolar IC50 values, with compounds 4c, 4d, and 4e showing the strongest activity (2.1-4.5 mu M), surpassing the reference drug Tamoxifen. Overall, the results indicate that diclofenac hydrazones represent promising candidates anticancer properties through MAPK14 inhibition, providing a foundation for the development of next-generation therapeutics against breast cancer.
  • Article
    Safety and Efficacy of Colchicine in COVID-19 Treatment: Systematic Review and Meta-Analysis
    (Elsevier, 2025) Nada, Ahmed Hosney; Ibrahim, Ismail A.; Asar, Nada Khalid; Qenawy, Abdulrahman; Mohammed, Mariam M.; Wagdy, Mohamed; Farouk, Heidi Sherif
    Background: Colchicine is an anti-inflammatory drug used for the treatment of gout and other autoinflammatory conditions. Several trials reported promising results of the efficacy of colchicine in Covid-19 due to its antiinflammatory properties. However, applying these results to clinical settings remains the subject of ongoing research. Methods: We performed a systematic review and meta-analysis on the efficacy and safety of colchicine in the treatment of Covid-19. PubMed, Cochrane Library, Web of Science, and Scopus were searched for relevant studies. The primary outcomes were 28-day mortality, invasive mechanical ventilation, non-invasive mechanical ventilation, and ICU admissions. The risk ratio was used to compare effectiveness between the two groups. Subgroup analysis was done for C-reactive protein and duration of hospitalization. Results: 17 randomized controlled trials with a total of 25478 patients were included. The overall Risk ratio didn't favor any of the two groups in terms of 28-day mortality (RR =1.03, 95 % CI [0.93:1.15], P = 0.58), noninvasive mechanical ventilation (RR = 0.81, 95 % CI [0.44:1.48], P = 0.49), ICU admission (RR = 0.89, 95 % CI [0.56:1.41], P = 0.62). The overall mean difference (MD) did not show statistical significance between both groups in terms of Creactive protein (CRP) (mg/dl) (MD = -1.21, 95 % CI [-2.42:0.01], P = 0.05), lactate dehydrogenase (LDH) (U/ L) (MD = 50.95, 95 % CI [-92.07: 193.98], Ferritin (ng/ml) (MD = 128.08, 95 % CI [51.97:204.18], P = 0.001), ICU length of stay (MD = -0.09, 95 % CI [-0.34:0.15], P = 0.45) and duration of hospitalization (MD = -0.41, 95 % CI [-1.56:0.73], P = 0.48). Conclusion: In Covid-19 treatment, colchicine didn't result in significant benefits in terms of clinical outcomes. More large-scale randomized clinical trials with standardized dosages and long-term follow-up are needed for further investigation into the colchicine effect.
  • Conference Object
  • Conference Object
    Motor Imagery-Based Individualized Alpha Transcranial Alternating Current Stimulation: Effects on Brain Oscillations and Motor Function
    (Elsevier, 2025) Aktuerka, Tuba; Bingol, Elifnur; Bas, Busra; Varolgunes, Yaren; Karadag, Gizem; Unsal, Esra; Guntekin, Bahar
  • Article
    Citation - WoS: 2
    Citation - Scopus: 2
    Novel Triazole-Urea Hybrids as Promising EGFR Inhibitors: Synthesis, Molecular Modeling and Antiproliferative Activity Studies Against Breast Cancer
    (Elsevier, 2025) Ture, Asli; Gulcan, Mehmet Metehan; Birgul, Serap Ipek Dingis; Erdogan, Oguz; Erdogan, Omer; Tuncay, Fulya Oz; Kucukguzel, Ilkay; Öz Tuncay, Fulya; Dingiş Birgül, Serap İpek
    Breast cancer is the second leading cause of mortality among women globally. In this study, novel promising urea derivatives containing a 4-phenyl-5-sulphanylidene-4,5-dihydro-1H-1,2,4-triazole group were synthesized and evaluated for their biological activities against breast cancer. The cytotoxicity and apoptotic profiles of these compounds were assessed on the MCF7 breast cancer cell line and the L929 fibroblast cell line. Compound 5c exhibited the strongest anticancer activity against MCF7 cells with an IC50 value of 56.97+4.22 mu M, while it showed significantly lower cytotoxicity against L929 cells (IC50 = 1651+18.39 mu M). Compound 5c also induced early apoptosis in MCF7 cells, with an apoptosis rate of 18.40% and 5.28%, respectively. Additionally, the EGFR inhibitory activities of the synthesized compounds were evaluated, with compound 5i demonstrating the most potent EGFR inhibition, showing an IC50 value of 35.1 nM. These results suggest that compound 5c likely exerts its anticancer effects through mechanisms other than EGFR inhibition, while compound 5i has significant potential as an effective EGFR inhibitor. Molecular modeling studies were conducted to suggest putative binding interactions of compounds 5d, 5e and 5i with wildtype hEGFR. Further studies are warranted to explore their activity against other cancer types.
  • Conference Object
    Gait Dynamics and Locomotor Function in Familial Mediterranean Fever: A Comparative Study with Healthy Peers
    (Elsevier, 2025) Seker, A. Namli; Albayrak, A.; Yekdaneh, A.; Akgun, O.; Ayaz, N. Aktay
  • Conference Object
  • Conference Object
    Is It Fear or Pain Understanding It's Impact on Physical Performance and Rumination in Children with Rheumatic Diseases
    (Elsevier, 2025) Donmez, I.; Arman, N.; Yekdaneh, A.; Albayrak, A.; Acikgoz, Y.; Ayaz, N. Aktay